Home › receptor
 

Keywords :   


Tag: receptor

Mercks Insomnia Medicine BELSOMRA (suvorexant) C-IV, the First and Only Orexin Receptor Antagonist, Now Available in the United States

2015-02-03 14:00:00| Merck.com - Product News

Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that BELSOMRA (suvorexant) is now available at pharmacies in the United States for the treatment of insomnia in adults who have difficulty falling asleep and/or staying asleep. BELSOMRA is the only orexin receptor antagonist approved for the treatment of insomnia in the United States. Orexin is one of the many neurotransmitters in the brain involved in promoting wakefulness, and BELSOMRA selectively blocks orexin receptors. Language: English Contact: Merck & Co., Inc.Media:Pam Eisele, 267-305-3558orMegan Wilkinson, 267-305-6463orInvestor:Justin Holko, 908-740-1879orJoe Romanelli, 908-740-1986 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: the united states medicine

 

Results of Phase II PRECEDENT Trial for Investigational Folate Receptor Therapy Vintafolide in Patients with Platinum-Resistant Ovarian Cancer Published in Journal of Clinical Oncology

2013-10-14 23:02:00| Merck.com - Research & Development News

Dateline City: WHITEHOUSE STATION N.J., & WEST LAFAYETTE, Ind. Merck and Endocytes Phase III PROCEED pivotal trial of vintafolide in ovarian cancer ongoing WHITEHOUSE STATION N.J., & WEST LAFAYETTE, Ind.--(BUSINESS WIRE)--Merck, known as MSD outside the United States and Canada, (NYSE: MRK) and Endocyte, Inc. (NASDAQ: ECYT) today announced the online publication of results from the randomized Phase II PRECEDENT trial for vintafolide (MK-8109/EC145), an investigational folate small molecule drug conjugate (SMDC), in the Journal of Clinical Oncology (JCO), the official journal of the American Society of Clinical Oncology. Language: English Contact: MerckMedia:Caroline Lappetito,267-305-7639Caroline.Lappetito@Merck.comorClaire Mulhearn, 908-423-7425Claire.Mulhearn@Merck.comorInvestors:Carol Ferguson, 908-423-4465Carol.Ferguson@Merck.comorJustin Holko, 908-423-5088Justin_Holko@Merck.comorEndocyteMedia:Tony Russo, 212-845-4251Tony.Russo@Russopartnersllc.comorMartina Schwarzkopf, 212-845-4292Martina.Schwarzkopf@Russopartnersllc.comorInvestors:Stephanie Ascher, 212-362-1200Stephanie@sternir.com Ticker Slug: Ticker: MRK Exchange: NYSE Ticker: ECYT Exchange: NASDAQ read more

Tags: of results journal published

 

Sites : [1] [2]